A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer
Conditions: Gastric Cancer/Adenocarcinoma of Esophagogastric Junction Interventions: Drug: Fruquintinib 、Nivolumab、Sintilimab、Oxaliplatin、Teysuno、Capecitabine Sponsors: Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 6, 2023 Category: Research Source Type: clinical trials
A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors
Conditions: Breast Neoplasms; Gastroesophageal Junction Adenocarcinoma; HER2 Low Breast Neoplasms; HER2 Positive Breast Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms Interventions: Drug: disitamab vedotin; Drug: tucatinib Sponsors: Seagen Inc.; RemeGen Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 6, 2023 Category: Research Source Type: clinical trials
A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors
Conditions: HER2 Expressing or Mutated Advanced Malignant Solid Tumors Interventions: Drug: GQ1005 Sponsors: GeneQuantum Healthcare (Suzhou) Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 4, 2023 Category: Research Source Type: clinical trials
Genentech Announces Positive Phase III Results for Inavolisib Combination in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
Phase III (INAVO120) results shows that inavolisib in combination with palbociclib and fulvestrant significantly improved progression-free survival in the first-line setting
PIK3CA mutations, found in approximately 40% of HR-positive... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 4, 2023 Category: Pharmaceuticals Source Type: clinical trials
Pyrotinib Combined With Capecitabine and Bevacizumab for Patients With HER2 Positive Breast Cancer and Brain Metastases
Conditions: Breast Cancer With Brain Metastases Interventions: Drug: pyrotinib+capecitabine+bevacizumab Sponsors: Tongji Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 1, 2023 Category: Research Source Type: clinical trials
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
Conditions: Lung Cancer, Non-squamous, Non-small Cell Interventions: Drug: zongertinib; Drug: pembrolizumab; Drug: cisplatin; Drug: carboplatin; Drug: pemetrexed Sponsors: Boehringer Ingelheim Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 30, 2023 Category: Research Source Type: clinical trials
Impact of a Predictive Model on Sentinel Lymph Node Biopsy in Initially Lymph Node-positive, HER2-positive Breast Cancer
Conditions: Breast Cancer; Sentinel Lymph Node Interventions: Procedure: Test cohort Sponsors: Fujian Medical University Union Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 29, 2023 Category: Research Source Type: clinical trials
eFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast Cancer
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 28, 2023 Category: Pharmaceuticals Source Type: clinical trials
A Prospective NIS to Evaluate the Clinical Outcomes of Risarg ® (Ribociclib) Combined With Endocrine Therapy or Chemotherapy in Patients With HR+HER2 - aBC in Routine Clinical Practice in the Russia
Conditions: HR+HER2- Advanced Breast Cancer Interventions: Other: Ribociclib; Other: Combination chemotherapy Sponsors: Novartis Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 28, 2023 Category: Research Source Type: clinical trials
Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer
Conditions: Breast Cancer Interventions: Drug: Adebrelimab; Drug: dalpiciclib Sponsors: Tongji Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 28, 2023 Category: Research Source Type: clinical trials
Single Center Registration Study on HER2 Expression and Clinical Pathological Characteristics in Prostate Cancer
Conditions: HER2 Expression and Clinical Pathological Characteristics in Prostate Cancer Interventions: Diagnostic Test: Collect HER2 expression in prostate cancer patients Sponsors: Qilu Hospital of Shandong University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 24, 2023 Category: Research Source Type: clinical trials
Paclitaxel Polymeric Micelles for Injection Versus TPC on the Treatment of HER2-negative Metastatic Breast Cancer (MBC).
Conditions: Metastatic Breast Cancer (MBC) Interventions: Drug: Paclitaxel Polymeric Micelles for Injection; Drug: Eribulin Mesilate injection; Drug: Capecitabine Tablets; Drug: Gemcitabine Hydrochloride for Injection; Drug: Vinorelbine Tartrate Injection; Drug: Paclitaxel (albumin-bound) Sponsors: Shanghai Yizhong Pharmaceutical Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 22, 2023 Category: Research Source Type: clinical trials
Neoadjuvant Pyrotinib Versus Placebo Combined With Chemotherapy in HR-positive and HER2-low Early Breast Cancer
Conditions: Breast Cancer Invasive; Hormone-receptor-positive Breast Cancer; HER2 Low Breast Carcinoma; Early-stage Breast Cancer Interventions: Drug: Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel; Drug: Placebo, epirubicin or doxorubicin, cyclophosphamide, paclitaxel Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 22, 2023 Category: Research Source Type: clinical trials
Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis
Conditions: Breast Carcinoma; Metastatic Malignant Neoplasm in the Brain; Metastatic Malignant Neoplasm in the Leptomeninges Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging; Radiation: Radiation Therapy; Procedure: Resection; Drug: Trotabresib; Drug: Vinorelbine Sponsors: Northwestern University; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2023 Category: Research Source Type: clinical trials
Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)
Conditions: Malignant Solid Neoplasm Interventions: Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Echocardiography; Biological: Pertuzumab; Procedure: Radiologic Examination; Biological: Trastuzumab Sponsors: National Cancer Institute (NCI) Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2023 Category: Research Source Type: clinical trials
